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Cardiac Strain as a Universal Biomarker
Interpreting the Sounds of Uneasy Heart Muscle CellsPartho P. Sengupta, MD, Jagat Narula, MD, PHDNew York, New Yorkhe heart is home to one of the most me-
chanically dynamic environments in the body.
Blood distends the heart chambers (diastole),
and a wave of contraction (systole) empties
the loaded chamber. At the tissue level, the load
stretches the myocytes with subsequent shortening
to create cyclic deformations (strain). The overall
force generated leads to pulsatile pressure change
(stress), with concurrent mechanical, electrical, and
molecular feedback and modulation of the contrac-
tile machinery of the heart muscle cells. In this issue
of iJACC, Cordero-Reyes et al. (1) provide signiﬁ-
cant evidence that myocardial contraction, as deﬁned
by noninvasive strain imaging, is correlated with the
expression of elements involved in force generation
and relaxation at the cellular level in patients with
dilated cardiomyopathy. In this page, we propose
cardiac strain as a universal biomarker for tracking
the changes in the dynamic biological milieu of the
functioning cardiomyocytes.
Myocyte Versus Myocardial Strain
Cardiomyocyte deformation can be directly
measured using nondestructive and noncontact optical
techniques for submicrometer tracking of myocytes
using ﬂuorescently labeled molecules or simple
ﬁduciary particles within or over cells (2). A car-
diomyocyte in a physiologically loaded state con-
tracts approximately 15% to 20% along its long axis,
although the magnitude of shortening can vary for
in vitro preparations. Interestingly, myocardial
regional strain obtained from the whole heart using
echocardiographic and magnetic resonance tissue
tracking, although dependent on software algo-
rithms, also ranges between 15% and 25%. SlightlyFrom the Icahn School of Medicine at Mount Sinai, New York, New
York. Both authors have reported that they have no relationships relevant
to the contents of this paper to disclose.higher strain noted near the apical ends of the left
ventricle may be related to tissue shear (longitudi-
nal-circumferential shear or torsion). Although
2-dimensional echocardiography may somewhat
overestimate strain because of the presence of
through-plane motion (3), it is rather intriguing that
strain measurement at the myocyte level and that
obtained by myocardial tissue tracking so closely
resemble each other in magnitude and temporal
pattern. There is a wealth of experimental evidence
relating myocardial tissue contraction using
in vitro techniques in tissue (Fig. 1) or single-cell
preparations for determining the molecular mecha-
nism underlying myocardial function. It would be
interesting to compare myocyte shortening as seen
on in vitro tracking techniques with that obtained
on cardiac imaging–based tissue-tracking techniques
for relating cardiac strain with cardiomyocyte func-
tional behavior within a given disease phenotype.
Cellular Processes Related to Myocardial Strain
The sarcomere consists of numerous proteins and an
even larger number connect them with the intra-
cellular and extracellular matrix to delicately regulate
muscle contraction from beat to beat. At the mo-
lecular level, the fulcrum of the contractile process
is the changing concentrations of Ca2þ ions in the
myocardial cytosol. In the failing heart, there are
changes in gene expression, including down-
regulation of the calcium uptake pump (SERCA2)
(4,5). Cordero-Reyes et al. (1) report an association
between cardiac strain and SERCA2 and phos-
pholamban (a SERCA modulator) expression.
Indeed, attempts to normalize SERCA2 expression
by adenoviral gene transfer in experimental models
in vivo have been reported to be associated with
increased cardiomyocyte-shortening strain (6).
Taken together, the existing data suggest that sys-
tolic calcium release and diastolic calcium reuptake
Figure 1. Direct Strain Analysis in Human Cardiomyocytes Versus Noninvasive Strain Assessments From Cardiac Imaging
(A) Fluorescent images of living cardiomyocytes (green) and injured cells (red, arrows) in a healthy engineered cardiac tissue (top) and
10 min after local cryoinjury (bottom) (scale bar, 1 mm). (B) Regional ﬁnite strains along the ECT axis (E11) versus time (seconds), indicating a
change from normal systolic shortening (open circles) to local paradoxical stretching (arrow) in the cryoinjury zone. In comparison, delayed
gadolinium enhanced cardiac magnetic resonance (C) shows a scarred interventricular septum in a patient with an old myocardial infarction
(arrows). Circumferential strain (percent) versus time (milliseconds) derived by speckle-tracking echocardiography (D) shows paradoxical
stretch (arrow) in the areas of scarred myocardium. Panels A and B are courtesy of Kevin Costa, PhD, Cardiovascular Research Center, Icahn
School of Medicine at Mount Sinai, New York, New York.
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535are key determinants of cardiac deformation. Strain
imaging as a quantitative tool may have a potential
role in guiding and interpreting cardiac deforma-
tion after therapies aimed at enhancing calcium
reuptake mechanisms, and therefore, merits further
investigation.
Consistent with previous observations (7),
Cordero-Reyes et al. (1) also note that myocardial
stiffness and diastolic relaxation were closely related
to isoforms of titin, the giant endosarcomeric pro-
tein that contributes to diastolic restoration forces.
Overall, these data suggest that the changes seen in
cardiac strain imaging primarily track car-
diomyocyte deformation rather than passive alter-
ations in the material properties of myocardium.
Further studies are needed to validate these re-
lationships in other phenotypic presentations and
important molecular targets for gene therapy, such
as protein phosphatase-1 and inhibitor protein 1,
beta-adrenergic receptors, the G protein–coupled re-
ceptor kinase 2 system, renin-angiotensin-aldosteronereceptors, and adenylyl cyclase activity, to name a
few (8).
Cardiac Strain and Subclinical Cardiac Dysfunction
In recent years, there has been growing interest in
using cardiac strain as a marker of subclinical cardiac
disease. For example, myocardial strain is attenuated
in asymptomatic patients with diabetes mellitus,
hypertension, smoking, obesity, and subclinical
atherosclerosis (9). Similarly, patients with endo-
crine abnormalities, renal disease, cerebral white
matter disease, and inﬂammatory arthritis may show
reductions in myocardial strain despite no evidence
of myocardial involvement. These observations
become more relevant because of the emerging
epidemic of noncommunicable diseases, particularly
obesity, which is associated with a clustering of risk
factors such as hyperlipidemia, hyperleptinemia,
hyperinsulinemia, insulin resistance, elevated circu-
lating cytokines, hypertension, and type 2 diabetes.
Cardiac strain is reduced in all these milieus and
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536may result from impaired activity of calcium reup-
take mechanisms. Experimental data suggest that
insulin resistance and related metabolic disorders are
associated with elevated oxidative stress and
increased SERCA2 oxidation, resulting in pro-
longed Ca2þ transients (10). The higher oxidative
stress also triggers inﬂammation and down-
regulation of mitochondrial energetics, which
further reduce myocyte function. Moreover, increased
insulin stimulates the renin-angiotensin signaling
pathway and consequently cardiomyocyte hyper-
trophy and cardiac ﬁbrosis. Maladapted hypertro-
phy may trigger cardiomyocyte death through
heightened apoptosis and autophagy, causing
progressive cardiac remodeling and heart failure
(11). Currently, interventions to address car-
diomyocyte distress and cell death and survival
pathways remain an exciting area of translational
research (12). In particular, modulation of insulin-
like growth factor 1 has been shown have a unique
role in the upregulation of prosurvival mechanisms,
with defense offered simultaneously against dia-
betes, cancer, and cardiovascular diseases (13).
With the emergence of such novel targets, cardiacstrain therefore may ﬁnd a role in identifying
subclinical myocyte dysfunction that results from
increased oxidative stress amid a milieu of risk
factors and subclinical diseases.
Recently, the emphasis has been placed on
addressing the growth of cost-effective, high-
throughput genomic and epigenomic analytics that
can underpin common molecular pathways. In
particular, there is a need to focus on developing
system-based approaches in cardiovascular diseases
that correlate cardiomyocyte gene expression and
molecular pathways with phenotypic and functional
imaging of pathology (14). With the burgeoning
ﬁeld of nanotechnology and cell-based therapy (15),
the standardization of cardiac strain may aid in the
early recognition of disease, clusters of risk factors,
and comorbidities that result in cardiomyocyte
contractile dysfunction. We believe that strain may
be subclinical sign of uneasy heart muscle cells.
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